CTOs on the Move

Grail

www.grail.com

 
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products for the early detection of cancer. The company is located in Menlo Park, California. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.grail.com
  • 1525 O`Brien Drive
    Menlo Park, CA USA 94025
  • Phone: 650.542.0372

Executives

Name Title Contact Details
Janet G.
 Head of Security Profile
Satnam Alag
 Senior Vice President of Software Engineering Profile
Angela Lai
 Chief Technology Officer Profile

Funding

Grail raised $125M on 12/16/2019
Grail raised $390M on 05/06/2020

Similar Companies

Fremont Analytical Inc

Fremont Analytical Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biostar Ventures

BioStar Ventures continues to build a solid track record as an early-stage, value-added venture investor in disruptive cardiovascular and orthopaedic medical technologies by combining the insight of seasoned venture capitalists with the expertise of world-renowned medical thought leaders in clinical practice to attract unique deal flow, mitigate investment risk, optimize product development, and secure successful exit.

BenevolentAI

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange.

Dharmacon Research

Dharmacon Research is a Lafayette, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Forty Seven

With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.